Citation Impact
Citing Papers
New approaches and procedures for cancer treatment: Current perspectives
2021 Standout
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
Phase IIB Multicenter Trial of Vorinostat in Patients With Persistent, Progressive, or Treatment Refractory Cutaneous T-Cell Lymphoma
2007 Standout
Crippling life support for SARS-CoV-2 and other viruses through synthetic lethality
2020 StandoutNobel
Breast cancer
2019 Standout
The Role of Short-Chain Fatty Acids in Health and Disease
2014 Standout
Lung cancer epigenetics: From knowledge to applications
2017
Histone Deacetylase Inhibitors in the Treatment of Hematological Malignancies and Solid Tumors
2010
Cardiac Involvement with Lymphoma: A Review of the Literature
2008
Cellular senescence: when bad things happen to good cells
2007 Standout
TGF-β: the master regulator of fibrosis
2016 Standout
Will broad-spectrum histone deacetylase inhibitors be superseded by more specific compounds?
2006
Epidemiology of chronic kidney disease: an update 2022
2022 Standout
Cancer Epigenetics: From Mechanism to Therapy
2012 Standout
Histone Deacetylase Inhibitors and Demethylating Agents: Clinical Development of Histone Deacetylase Inhibitors for Cancer Therapy
2007
Blocking the Class I Histone Deacetylase Ameliorates Renal Fibrosis and Inhibits Renal Fibroblast Activation via Modulating TGF-Beta and EGFR Signaling
2013
Cancer stem cells revisited
2017 Standout
The Epigenomics of Cancer
2007 Standout
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
2010 Standout
Anticancer activities of histone deacetylase inhibitors
2006 Standout
Epigenetics in cancer
2009 Standout
Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents
2010
Natural products to drugs: natural product-derived compounds in clinical trials
2008 Standout
Cell-free nucleic acids as biomarkers in cancer patients
2011 Standout
Pyroptosis: mechanisms and diseases
2021 Standout
Anchor extension: a structure-guided approach to design cyclic peptides targeting enzyme active sites
2021 StandoutNobel
Epigenetic treatment of solid tumours: a review of clinical trials
2015
Causes and consequences of microRNA dysregulation in cancer
2009 Standout
Light‐Controlled Histone Deacetylase (HDAC) Inhibitors: Towards Photopharmacological Chemotherapy
2015 StandoutNobel
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
Gut microbiota, metabolites and host immunity
2016 Standout
Paul Ehrlich's magic bullet concept: 100 years of progress
2008 Standout
Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells
2009
Epigenetic modifications and human disease
2010 Standout
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
2006 Standout
Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation
2013 StandoutNature
miR-449a targets HDAC-1 and induces growth arrest in prostate cancer
2009
Chromatin, cancer and drug therapies
2008
Photothermal therapy and photoacoustic imaging via nanotheranostics in fighting cancer
2018 Standout
Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma
2009 Standout
Nanomaterials for In Vivo Imaging
2017
Chronic Kidney Disease Diagnosis and Management
2019 Standout
Use of Radiocontrast Agents in CKD and ESRD
2017
Cardiac Studies in Patients Treated with Depsipeptide, FK228, in a Phase II Trial for T-Cell Lymphoma
2006
New and emerging HDAC inhibitors for cancer treatment
2014
Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase Inhibitor
2013
Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs.
2011
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
Molecularly Targeted Oncology Therapeutics and Prolongation of the QT Interval
2007
Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias
2006
Transcriptional control of human p53-regulated genes
2008 Standout
Single-nanometer iron oxide nanoparticles as tissue-permeable MRI contrast agents
2021 StandoutNobel
Combination therapy in combating cancer
2017 Standout
Histone Deacetylase Inhibitors: From Bench to Clinic
2008
The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition
2014 Standout
Histone Deacetylase Inhibitors in Cancer Therapy
2009
Targeted Cancer Therapy: Giving Histone Deacetylase Inhibitors All They Need To Succeed
2012
Impact of Natural Products on Developing New Anti-Cancer Agents
2009 Standout
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
2007 Standout
Synthesis and Histone Deacetylase Inhibitory Activity of Largazole Analogs: Alteration of the Zinc-Binding Domain and Macrocyclic Scaffold
2009
Hemodialysis Disparities in African Americans: The Deeply Integrated Concept of Race in the Social Fabric of Our Society
2017
Fast detection of liver fibrosis with collagen-binding single-nanometer iron oxide nanoparticles via T 1 -weighted MRI
2023 StandoutNobel
Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection
2010
Chemistry of MRI Contrast Agents: Current Challenges and New Frontiers
2018
Works of Qin Ryan being referenced
Fluorodeoxyglucose Positron Emission Tomography in the Presence of Cardiac Metastases
2003
Comparative Risk of Anaphylactic Reactions Associated With Intravenous Iron Products
2015
Phase I and Pharmacokinetic Study of MS-275, a Histone Deacetylase Inhibitor, in Patients With Advanced and Refractory Solid Tumors or Lymphoma
2005
Histone deacetylase inhibitor pharmacodynamic analysis by multiparameter flow cytometry.
2005
Phase I Trial of MS-275, a Histone Deacetylase Inhibitor, Administered Weekly in Refractory Solid Tumors and Lymphoid Malignancies
2007
Association Between Changes in CMS Reimbursement Policy and Drug Labels for Erythrocyte-Stimulating Agents With Outcomes for Older Patients Undergoing Hemodialysis Covered by Fee-for-Service Medicare
2016